Quarterly Update

Gary Phillips, CEO

1st August 2025

Forward looking statement

This document contains forward-looking statements, including statements concerning Syntara's future financial position, plans, and the potential of its products and product candidates, which are based on information and assumptions available to Syntara as of the date of this document. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements.

These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

Highlights

- **Amsulostat builds momentum:**
  - The WHO grants the International Non-Proprietary Name (INN) of amsulostat to SNT-5505
  - FDA Fast Track designation received for amsulostat for the treatment of myelofibrosis
  - **Positive interim Phase 2 clinical data for amsulostat presented at the European Hematology Conference**
  - Phase 1c/2 AZALOX clinical study of amsulostat in second blood cancer, myelodysplastic syndrome (MDS), initiated
  - Strong interest in amsulostat at BIO partnering conference
  - FDA Type C meeting lodged to discuss clinical development plan for amsulostat
- Skin scarring program moves into gear:
  - First patient dosed in the Phase 1a/b trial, evaluating SNT-9465 for the treatment of hypertrophic scars
  - First patient dosed in the Phase 1c SATELLITE trial, evaluating SNT-6302 for the treatment of keloid scars
- IRBD / Parkinson's Disease Phase 2 study 50% recruited – on track to report in 1H 2026
- Syntara ends the quarter with a strong cash position of $15.1m

Myelofibrosis phase 2 study interim data conclusions

Interim data[1] suggests that amsulostat combined with ruxolitinib may deliver deep and long-lasting benefit to patients who are sub-optimally controlled on ruxolitinib alone

Consistent with monotherapy data[2], amsulostat is safe and well tolerated in combination with RUX in a broad population with high disease burden

Despite the relatively small sample size the absolute improvement in symptom score and the number of patients who achieve a TSS50 is very encouraging

Reductions in symptoms and spleen volume that continue to improve over time is a novel finding that indicates amsulostat has the potential to provide a significantly different and well tolerated treatment option for patients on a JAK inhibitor

Remaining 3 patients in study scheduled to complete 12 months treatment in Q3 2025.

FDA guidance on progression to pivotal study sought by Q3 2025.

Encouraging interim Phase 2a data sets amsulostat on a clear clinical and regulatory pathway to commercial value

[1] Watson et al EHA 2025 and Tan et al ASH 2024. [2] Vachhani P, et al. Blood 142 (2023) 625–627

Targeting Multiple Near Term Opportunities in High Value Markets

Drug Candidate	Indication	Phase	Anticipated Upcoming Milestones	Addressable market (US$)
Amsulostat	Myelofibrosis	Phase 2	Interim 12 month data June 2025	**~$1 billion[1]**
	Myelodysplastic Syndrome Low & intermediate Risk + High risk trials	Phase 1c/2	Interim Data H1 2026	**~$3.2 billion[2]**
SNT-9465	Hypertrophic Scars	Phase 1a/b	Data H1 2026	**~$3.5 billion[3]**
SNT-6302	Keloid Scars	Phase 1c	Pilot study in keloid scars planned	**~$3.5 billion[3]**
SNT-4728	IRBD and Parkinson's Disease	Phase 2	Data H1 2026	**~$3.5 billion[4]**

[1] MF: Addressable market, The Myelofibrosis market size across the 8MM was valued at $2.39 billion in 2021 : https://www.globaldata.com/store/report/myelofibrosis-market-analysis/
[2] MDS: Addressable market, MYELODYSPLASTIC SYNDROME TREATMENT MARKET ANALYSIS, https://www.coherentmarketinsights.com/market-insight/myelodysplastic-syndrome-treatment-market-775
[3] Scar modification: Addressable market, Global Scar Market 2020 page 40 and 71. Total scar treatment market in 2019 exceeded US$19b. Keloid and hypertrophic scar segment ~US$3.5b
[4] IRBD / Parkinson's Addressable market, Parkinson's Disease market size across the 7MM was valued at $3.4 billion in 2019 and is expected to achieve a CAGR of more than 6% during 2019-2029. https://www.globaldata.com/store/report/parkinsons-disease-major-market-analysis/

Recent & Anticipated News Flow

Strong and growing pipeline with advancement in studies expected to provide value inflection points



Key Events Q3 25

- Outcome of FDA review of amsulostat Phase 2/3 clinical trial proposal
- Final 12 month data from amsulostat MF combination study

Syntara Limited ABN 75 082 811 630

Gary Phillips
Chief Executive Officer
gary.phillips@syntaraTX.com.au

www.syntaraTX.com.au